Biotech · Private company · Raleigh, NC, US
Geneventiv Therapeutics, Inc.
Track this companyFree. Adds Geneventiv Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of a universal gene therapy for hemophilia A or B with or without inhibitorsFiscal year 2025 · $45.3KNIH RePORTER 3R44HL174236-02S1 · fetched Nov 12, 2026
- Development of a universal gene therapy for hemophilia A or B with or without inhibitorsFiscal year 2025 · $1.3MNIH RePORTER 5R44HL174236-02 · fetched Nov 12, 2026
- Development of a universal gene therapy for hemophilia A or B with or without inhibitorsFiscal year 2024 · $1.2MNIH RePORTER 1R44HL174236-01 · fetched Nov 12, 2026